Investors: Biologics are 'hot' right now

Kate Bingham, managing partner at SV Life Sciences, says that biologics are "hot" right now for investors. Speaking at a European conference, Bingham said that deal-making and greater innovation were driving the growth of the continent's biotech sector. "Innovation is being concentrated on drugs being prescribed by specialists in hospitals," she told the group, with antibodies also attracting a lot of attention.

- read the report from AFX

Related Articles:
MAbs are hottest segment of biotech industry. Report
Sanofi: We're looking for biotech deals. Report
Pfizer's future rests with biotech. Report
Lines blur as Big Pharma crosses borders into biotech. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.